Trial Profile
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Decitabine (Primary) ; Natural killer cell therapy (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 05 Mar 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 03 Apr 2018 Status changed from recruiting to active, no longer recruiting.